Online inquiry

IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5493MR)

This product GTTS-WQ5493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5493MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1846MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ13854MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ13309MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ4524MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ9781MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ3911MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ6848MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ375MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW